207 related articles for article (PubMed ID: 32832675)
1. Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations.
Mandal A; Kumbhojkar N; Reilly C; Dharamdasani V; Ukidve A; Ingber DE; Mitragotri S
Sci Adv; 2020 Jul; 6(30):eabb6049. PubMed ID: 32832675
[TBL] [Abstract][Full Text] [Related]
2. IkBζ is a Key Regulator of Tumour Necrosis Factor-a and Interleukin-17A-mediated Induction of Interleukin-36g in Human Keratinocytes.
Ovesen SK; Schulze-Osthoff K; Iversen L; Johansen C
Acta Derm Venereol; 2021 Feb; 101(2):adv00386. PubMed ID: 33491092
[TBL] [Abstract][Full Text] [Related]
3. The human IL-17A/F heterodimer regulates psoriasis-associated genes through IκBζ.
Bertelsen T; Iversen L; Johansen C
Exp Dermatol; 2018 Sep; 27(9):1048-1052. PubMed ID: 29938836
[TBL] [Abstract][Full Text] [Related]
4. IκBζ is a key player in the antipsoriatic effects of secukinumab.
Bertelsen T; Ljungberg C; Litman T; Huppertz C; Hennze R; Rønholt K; Iversen L; Johansen C
J Allergy Clin Immunol; 2020 Jan; 145(1):379-390. PubMed ID: 31622687
[TBL] [Abstract][Full Text] [Related]
5. Multifaceted targeting of cationic liposomes via co-delivery of anti-IL-17 siRNA and corticosteroid for topical treatment of psoriasis.
Yadav K; Singh D; Singh MR; Pradhan M
Med Hypotheses; 2020 Dec; 145():110322. PubMed ID: 33086162
[TBL] [Abstract][Full Text] [Related]
6. Topical delivery of siRNA into skin using ionic liquids.
Dharamdasani V; Mandal A; Qi QM; Suzuki I; Bentley MVLB; Mitragotri S
J Control Release; 2020 Jul; 323():475-482. PubMed ID: 32339547
[TBL] [Abstract][Full Text] [Related]
7. SERPINB2 and miR-146a/b are coordinately regulated and act in the suppression of psoriasis-associated inflammatory responses in keratinocytes.
Vaher H; Kivihall A; Runnel T; Raam L; Prans E; Maslovskaja J; Abram K; Kaldvee B; Mrowietz U; Weidinger S; Kingo K; Rebane A
Exp Dermatol; 2020 Jan; 29(1):51-60. PubMed ID: 31630447
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus Inhibits TNF-α/IL-17A-Produced pro-Inflammatory Effect on Human Keratinocytes by Regulating IκBζ.
Hu Y; Guo J; Yin L; Tu J; Yin Z
Inflammation; 2020 Apr; 43(2):692-700. PubMed ID: 31838663
[TBL] [Abstract][Full Text] [Related]
9. TNF-α-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-α blockade-driven IL-17A expression.
Urbano PCM; Aguirre-Gamboa R; Ashikov A; van Heeswijk B; Krippner-Heidenreich A; Tijssen H; Li Y; Azevedo VF; Smits LJT; Hoentjen F; Joosten I; Koenen HJPM
J Allergy Clin Immunol; 2018 Aug; 142(2):517-529. PubMed ID: 29248493
[TBL] [Abstract][Full Text] [Related]
10. Glycyrrhizin improves the pathogenesis of psoriasis partially through IL-17A and the SIRT1-STAT3 axis.
Qiong H; Han L; Zhang N; Chen H; Yan K; Zhang Z; Ma Y; Xu J
BMC Immunol; 2021 May; 22(1):34. PubMed ID: 34044769
[TBL] [Abstract][Full Text] [Related]
11. RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase.
Depieri LV; Borgheti-Cardoso LN; Campos PM; Otaguiri KK; Vicentini FT; Lopes LB; Fonseca MJ; Bentley MV
Eur J Pharm Biopharm; 2016 Aug; 105():50-8. PubMed ID: 27224855
[TBL] [Abstract][Full Text] [Related]
12. IL-17F regulates psoriasis-associated genes through IκBζ.
Bertelsen T; Ljungberg C; Boye Kjellerup R; Iversen L; Johansen C
Exp Dermatol; 2017 Mar; 26(3):234-241. PubMed ID: 27576147
[TBL] [Abstract][Full Text] [Related]
13. The small molecule rhodomyrtone suppresses TNF-α and IL-17A-induced keratinocyte inflammatory responses: A potential new therapeutic for psoriasis.
Chorachoo J; Lambert S; Furnholm T; Roberts L; Reingold L; Auepemkiate S; Voravuthikunchai SP; Johnston A
PLoS One; 2018; 13(10):e0205340. PubMed ID: 30321197
[TBL] [Abstract][Full Text] [Related]
14. Transdermal delivery of Fn14 siRNA using a novel composite ionic liquid for treatment of psoriasis-like skin lesions.
Li L; Wu X; Wu J; Zhang X; Miao F; Wang J; Lu J; Liu J; Chen Z; Tai Z; Zhu Q
J Control Release; 2024 Jan; 365():818-832. PubMed ID: 38070601
[TBL] [Abstract][Full Text] [Related]
15. NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis.
Coto-Segura P; González-Lara L; Batalla A; Eiris N; Queiro R; Coto E
Mol Diagn Ther; 2019 Oct; 23(5):627-633. PubMed ID: 31267486
[TBL] [Abstract][Full Text] [Related]
16. Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.
Furue K; Ito T; Furue M
Cytokine; 2018 Nov; 111():182-188. PubMed ID: 30172115
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
[TBL] [Abstract][Full Text] [Related]
18. Biologics in pediatric psoriasis.
Wang WM; Jin HZ
J Dermatol; 2023 Apr; 50(4):415-421. PubMed ID: 36651087
[TBL] [Abstract][Full Text] [Related]
19. IL-17A synergistically enhances TLR3-mediated IL-36γ production by keratinocytes: A potential role in injury-amplified psoriatic inflammation.
Liu S; Wu F; Wu Z; Li Y; Zhang S; Yu N
Exp Dermatol; 2019 Mar; 28(3):233-239. PubMed ID: 30614571
[TBL] [Abstract][Full Text] [Related]
20. Ameliorative effects of a fusion protein dual targeting interleukin 17A and tumor necrosis factor α on imiquimod-induced psoriasis in mice.
Liu Z; Liu H; Xu P; Yin Q; Wang Y; Opoku YK; Yang J; Song L; Sun X; Zhang T; Yu D; Wang X; Ren G; Li D
Biomed Pharmacother; 2018 Dec; 108():1425-1434. PubMed ID: 30372845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
